The global hemoglobinopathies market valued at USD 6.9 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032. The market is poised to secure a market value of USD 15.9 billion by 2032, driven by the rising incidence of thalassemia and sickle cell anemia across the region.
The Latin America hemoglobinopathies market growth is expected to be driven by the increasing focus of researchers on developing effective treatments for hemoglobinopathies such as thalassemia and sickle cell disease. Researchers are more inclined toward finding and delivering the best technique, technology, and treatment for the management of chronic disease, propelling the market demand. For instance, in December 2023, University of Maryland School of Medicine (UMSOM) dean joined prominent scientists and government health officials at a symposium in Rio De Janeiro, Brazil, to discuss new treatments for sickle cell disease (SCD). The symposium highlighted the developments undergoing in a randomized multicenter clinical trial for Sickle Cell Disease and CardiovAscular Risk-Red Cell Exchange Trial (SCD-CARRE), conducted across 22 sites in Brazil, France, and the United States. Such events are projected to boost the Latin America hemoglobinopathies market share as conducting it among the diverse population of Brazil will not only make the trial challenging but rather contribute to increased efficiency and accuracy, helpful in becoming a standard treatment option.
The market is poised to be driven by the strategic initiatives of organisations to train health practitioners on safe blood irradiation practices. For instance, in November 2023, the International Atomic Energy Agency (IAEA) organized a regional training course on the safe delivery of blood irradiation services for health practitioners in Latin America and the Caribbean. 30+ experts from domains such as hematology, biochemistry, physics, quality assurance, and radiation technology were gathered to update and share their knowledge, and best practices, and learn from each other’s experiences. The emphasis on delivering immediate and quality care to the patients is one of the major Latin America hemoglobinopathies market trends expected to boost the market value positively in the forecast period.
Patients suffering from hemoglobinopathies like thalassemia and sickle cell disease require frequent blood transfusions. This training ensures that health practitioners are well-trained in delivering safer blood transfusions. Improved safety and efficacy of transfusions directly enhance patient outcomes and could lead to increased trust and reliance on transfusion services. This is likely to impact the market positively by improving the quality of care and increasing awareness about the necessary measures required to be taken during the process.
The Latin America hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
Organisations like the IAEA conducting training sessions for healthcare practitioners to learn the best practices from experts is a major trend influencing market growth.
What are the types of hemoglobinopathies?
Different types of hemoglobinopathies in the market are thalassemia, sickle cell disease and other Hb variant diseases.
What treatments for hemoglobinopathies are available in the market?
Treatments available for hemoglobinopathies include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, monoclonal antibody medication, and others.
What kind of tests are performed for hemoglobinopathies?
Type of tests includes routine red blood cell (RBC) Count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
Who are the end users in the market?
End users in the market include hospitals and clinics, and diagnostic laboratories among others.
What is the market segmentation by country?
The market segmentation by countries include Brazil, Argentina, Mexico, and others.
Who are the key players in the Latin America Hemoglobinopathies market?
The key players in the market are Abbott, Alnylam Pharmaceuticals, Inc., Biogen, Bristol-Myers Squibb Company, Danaher, Emmaus Medical, Inc., F. Hoffmann-La Roche Ltd, Gamida Cell, Global Blood Therapeutics, Inc., and Novartis.
This product will be delivered within 5-7 business days.
Latin America Hemoglobinopathies Market Outlook
- The rising incidence of sickle cell disease (SCD) and thalassemia, which are amongst the most prevalent hemoglobinopathies boosting the market demand in Latin American region.
- In November 2023, the IAEA trained over 30 Latin American and Caribbean health experts in blood irradiation, enhancing regional safety, standardization, and collaboration in medical practices. Such initiatives to drive awareness amongst healthcare providers is one of the significant Latin America hemoglobinopathies market trends.
- In December 2023, University of Maryland School of Medicine researchers discussed new sickle cell disease treatments at a symposium in Rio De Janeiro, Brazil, addressing the disease affecting 20 million globally. The establishment of such events underscores the emphasis on managing and treating hemoglobinopathies effectively.
Latin America Hemoglobinopathies Market Analysis
Hemoglobinopathies are a group of inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies. Sickle cell disease (SCD) is a group of hereditary chronic diseases that has significantly reduced the quality of life. The prevalence of HbS, (sickle hemoglobin) is quite common in Colombia, predominantly affecting males. The ancestry has influenced the distribution of hemoglobinopathies in different geographical regions of Colombia, driving the increasing number of cases in the market. Thalassemia is one of the common hemoglobinopathies as well.The Latin America hemoglobinopathies market growth is expected to be driven by the increasing focus of researchers on developing effective treatments for hemoglobinopathies such as thalassemia and sickle cell disease. Researchers are more inclined toward finding and delivering the best technique, technology, and treatment for the management of chronic disease, propelling the market demand. For instance, in December 2023, University of Maryland School of Medicine (UMSOM) dean joined prominent scientists and government health officials at a symposium in Rio De Janeiro, Brazil, to discuss new treatments for sickle cell disease (SCD). The symposium highlighted the developments undergoing in a randomized multicenter clinical trial for Sickle Cell Disease and CardiovAscular Risk-Red Cell Exchange Trial (SCD-CARRE), conducted across 22 sites in Brazil, France, and the United States. Such events are projected to boost the Latin America hemoglobinopathies market share as conducting it among the diverse population of Brazil will not only make the trial challenging but rather contribute to increased efficiency and accuracy, helpful in becoming a standard treatment option.
The market is poised to be driven by the strategic initiatives of organisations to train health practitioners on safe blood irradiation practices. For instance, in November 2023, the International Atomic Energy Agency (IAEA) organized a regional training course on the safe delivery of blood irradiation services for health practitioners in Latin America and the Caribbean. 30+ experts from domains such as hematology, biochemistry, physics, quality assurance, and radiation technology were gathered to update and share their knowledge, and best practices, and learn from each other’s experiences. The emphasis on delivering immediate and quality care to the patients is one of the major Latin America hemoglobinopathies market trends expected to boost the market value positively in the forecast period.
Patients suffering from hemoglobinopathies like thalassemia and sickle cell disease require frequent blood transfusions. This training ensures that health practitioners are well-trained in delivering safer blood transfusions. Improved safety and efficacy of transfusions directly enhance patient outcomes and could lead to increased trust and reliance on transfusion services. This is likely to impact the market positively by improving the quality of care and increasing awareness about the necessary measures required to be taken during the process.
Latin America Hemoglobinopathies Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Thalassemia
- Sickle Cell Disease
- Other Hb Variants Diseases
Market Breakup by Treatment
- Stem-Cell Transplantation
- Blood Transfusions
- Analgesics
- Antibiotics
- Ace Inhibitors
- Hydroxyurea
- Monoclonal Antibody Medication
- Others
Market Breakup by Test Type
- Routine Red Blood Cell (RBC) Count
- Genetic Testing
- Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
- Hemoglobin Isoelectric Focusing (Hb IEF)
- Hemoglobin electrophoresis (Hb ELP)
- Hemoglobin Solubility Test
Market Breakup by End User
- Hospitals and Clinics
- Diagnostics Laboratories
- Others
Market Breakup by Country
- Brazil
- Argentina
- Mexico
- Others
Latin America Hemoglobinopathies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Abbott
- Alnylam Pharmaceuticals, Inc.
- Biogen
- Bristol-Myers Squibb Company
- Danaher
- Emmaus Medical, Inc.
- F. Hoffmann-La Roche Ltd
- Gamida Cell
- Global Blood Therapeutics, Inc.
- Novartis
FAQs
What was the Latin America hemoglobinopathies market forecast outlook for 2024-2032?The Latin America hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
What are the major factors aiding the Latin America hemoglobinopathies market demand? The increasing number of research activities to find new treatments for sickle cell disease and thalassemia are driving the market demand.
What are the major Latin America hemoglobinopathies market trends?Organisations like the IAEA conducting training sessions for healthcare practitioners to learn the best practices from experts is a major trend influencing market growth.
What are the types of hemoglobinopathies?
Different types of hemoglobinopathies in the market are thalassemia, sickle cell disease and other Hb variant diseases.
What treatments for hemoglobinopathies are available in the market?
Treatments available for hemoglobinopathies include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, monoclonal antibody medication, and others.
What kind of tests are performed for hemoglobinopathies?
Type of tests includes routine red blood cell (RBC) Count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
Who are the end users in the market?
End users in the market include hospitals and clinics, and diagnostic laboratories among others.
What is the market segmentation by country?
The market segmentation by countries include Brazil, Argentina, Mexico, and others.
Who are the key players in the Latin America Hemoglobinopathies market?
The key players in the market are Abbott, Alnylam Pharmaceuticals, Inc., Biogen, Bristol-Myers Squibb Company, Danaher, Emmaus Medical, Inc., F. Hoffmann-La Roche Ltd, Gamida Cell, Global Blood Therapeutics, Inc., and Novartis.
This product will be delivered within 5-7 business days.
Table of Contents
1 Preface
3 Latin America Hemoglobinopathies Market Overview
4 Latin America Hemoglobinopathies Market Landscape*
5 Latin America Hemoglobinopathies Market Dynamics
6 Latin America Hemoglobinopathies Market Segmentation (2017-2032)
7 Brazil Hemoglobinopathies Market (2017-2032)
8 Argentina Hemoglobinopathies Market (2017-2032)
9 Mexico Hemoglobinopathies Market (2017-2032)
11 Patent Analysis
12 Grants Analysis
13 Funding and Investment Analysis
14 Partnership and Collaborations Analysis
15 Supplier Landscape
16 Latin America Hemoglobinopathies Market - Distribution Model (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
19 Payment Methods (Additional Insight)
Companies Mentioned
- Abbott
- Alnylam Pharmaceuticals Inc.
- Biogen
- Bristol-Myers Squibb Company
- Danaher
- Emmaus Medical Inc.
- F. Hoffmann-La Roche Ltd
- Gamida Cell
- Global Blood Therapeutics Inc.
- Novartis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | June 2024 |
| Forecast Period | 2024 - 2032 |
| Estimated Market Value ( USD | $ 7.5 Billion |
| Forecasted Market Value ( USD | $ 15.9 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Latin America |
| No. of Companies Mentioned | 10 |
